A senior team gives you clear answers in weeks on patients, payers, competitors and revenue. For the teams deciding what to develop, license, launch or invest in.
sources used to rebuild the market
Claims estimate
Our rebuild
Medicaid patients added
The rebuild added a Medicaid population to the team’s estimate.
See our work
We answer the questions each stage raises while there’s still time to act on the answer.
Every forecast rests on a few assumptions: who is eligible, what payers will cover, what price they accept and how fast physicians prescribe. Each one starts as an estimate. We check them against published studies, payer policies and public data, so you commit budget on numbers that hold up.

Our Health Lake brings prescribing, procedure, payment and payer data together, so a project starts from data that is already in place.
public data sources catalogued in our Health Lake, most already cleaned and joined clinician by clinician
Public data first, your data if you want it
Most answers come from public sources. We add your own data only when it helps the question.
Sources picked for each decision
We also choose how to connect them and which model answers the decision in front of you.
20+ years in life sciences commercialization
Strategists with big pharma and small biotech experience interpret the results, and every number traces to its source.
We find the facts that settle the decision in front of you.
Public sources combine into one answer. Your own data is optional.
01
You bring a question
Tell us what’s pressing and what depends on it. We start by agreeing on the exact question to answer.
02
We pull together the public data that answers it
More than 900 public sources, from prescribing and payment data to payer policies and published studies, most already cleaned and joined in our Health Lake. If it helps, we add your own data or a few expert, patient or payer conversations.
03
You get the answer, and everything behind it
The answer and what to do about it. An executive read-out written for the room you need to convince.
Who to go after first, named, sized and ranked, when that’s what you need.
The sources and calculations behind each number, so your team can check our work.
A working session with your team to walk through it.
Senior life sciences strategists run every project from the first call to the final read-out.
Julie Batten
More than a decade of launches at big pharma and small biotech.
Part of the founding leadership team at Katalyst, a Klick company.
Brian O’Donnell
Leads how we combine public data into answers for commercial decisions.
20+ years in life sciences commercialization. Leads our use of AI to find and check sources.
Short reads on the markets we track and the numbers behind them. Request a copy of any read and we’ll email it to you.
CSU · OCT 2026
Three mechanisms now compete in chronic hives
For over a decade, CSU patients not controlled on antihistamines had one biologic option. Three mechanisms are now approved, and a fourth could follow by 2028. Here is the market after Celldex’s Phase 3 readout.
Request a copy
(5 pages)
PYODERMA GANGRENOSUM · SEPT 2026
Five signals that matter for a US launch in PG
A disease claims data barely sees. What public procedure, prescribing and payment data says about where patients are, who sees them first, and what a launch has to beat.
Request a copy
(4 pages)
IGA NEPHROPATHY · SEPT 2026
Six IgAN brands approved since 2021, all tested as add-on therapies
No late-stage IgAN trial goes head-to-head with an approved brand. Through 2028, brands compete on sequence and combination.
Request a copy
(2 pages)
We’re pre-approval. Isn’t it too early?
Pre-approval is often the best time to start. A market snapshot, a sizing or a check on your launch assumptions feeds your budget and launch plan before the big decisions are locked in.
We’re small and budgets are tight. Can we afford this?
Most teams use research budget already set aside and get answers in weeks instead of waiting on a six-month study. You can start with a market snapshot or one focused question a commercial lead can approve alone. There are no long contracts, and you can stop after any phase.
Our disease area has thin data.
That’s where combining many sources matters most. No single dataset sees a rare market well.
We already have an agency or insights team.
We work alongside them on the work they don’t have time for. We sell no media, creative or data.
Is this just AI?
AI helps us search more sources faster, and senior people check every result before it reaches you.
Tell us about your program and the decision ahead. Julie Batten will reply directly with how we’d approach it. Not ready yet? Request a market read or see the FAQ.
03
Second opinion
Pressure-test a forecast, plan or launch assumption before it goes to the board.
Start here
Julie Batten
Life Sciences Practice Lead
Bring us your question








